1. Clinical Pearl: The "Bottom Line" for Rounds
As clinicians, we must distinguish between a drug’s ability to bind a target (affinity) and its ability to trigger a biological response (efficacy); think of affinity (K_A) as the "lock-and-key" fit and efficacy (E) as the "turning of the bolt" that actually opens the door. A drug can occupy every receptor on a cell surface yet produce zero effect if it lacks the power to "flip the switch" into an active state.
Download the Textbook of Receptor Pharmacology pdf for free
2. Introduction
The transition from 19th-century herbalism to modern molecular pharmacology began with the purification of plant alkaloids such as nicotine and atropine. By observing how these substances influenced salivation and muscle contraction, J.N.
Langley identified "receptive substances" that acted as the gatekeepers of the autonomic nervous system. This logic was crystallized by Paul Ehrlich’s Latin principle, Corpora non agunt nisi fixata (Entities do not act unless attached).
Ehrlich’s "side chain theory" proposed that for a drug or toxin to manifest an effect, it must first be anchored to a specific cellular macromolecule—the receptor. Today, we define receptors as specialized proteins evolved for chemical signaling, capable of both ligand recognition and signal transduction.
3. Modeling Receptor Occupancy: The Hill-Langmuir Equation
To predict how a drug concentration [A] relates to receptor occupancy, we use the Hill-Langmuir equation. At the heart of this model is the equilibrium dissociation constant (K_A), defined as the concentration of drug required to occupy exactly 50% of the total receptor population. When we plot occupancy against the log-concentration of the drug, we observe a sigmoidal (S-shaped) curve.
The Attending's Distinction: Microscopic vs. Macroscopic Constants You must understand that the constant we measure in the lab or at the bedside is often the Macroscopic/Effective Equilibrium Constant (K_{eff}), which is not the same as the Microscopic Dissociation Constant (K_A).
The relationship is governed by the formula: K_{eff} = \frac{K_A}{1 + E} Because efficacy (E) drives the system toward the active state, a highly efficacious agonist will appear to have a higher "apparent" affinity (K_{eff}) than its true chemical binding affinity (K_A).
Clinical Pitfall: The Occupancy-Response Gap Never assume that a 50% clinical response (EC_{50}) equates to 50% receptor occupancy. In many tissues, the EC_{50} is significantly lower than the K_A due to signal amplification and tissue-specific factors.
4. Agonism: Understanding Intrinsic Activity and Efficacy
Drugs are classified by their intrinsic activity (\alpha), a descriptive value representing the relative maximum effect a drug can produce in a specific tissue.
.png)
R.P. Stephenson refined this with the concept of efficacy (e), noting that some agonists are so effective they require minimal occupancy to reach a "ceiling" response. These tissues possess spare receptors (receptor reserve).
Context is everything: The effectiveness of a partial agonist like prenalterol is highly environment-dependent. While it may act as a stimulant for heart rate in a resting state, its effects can be masked or abolished in "high-tone" environments.
For example, if carbachol (a muscarinic agonist) is present, it acts as a physiological antagonist by causing contraction that physically opposes the relaxation caused by prenalterol, effectively making the partial agonist's efficacy appear to vanish.
5. The Del Castillo-Katz Mechanism: The "Why" of Activation
Why does one drug "turn on" a receptor while another simply "sits" there? The Del Castillo-Katz mechanism explains this through isomerization—the shifting of the receptor from an inactive state (AR) to an active state (AR^*).
- Affinity (K_A): The initial binding step.
- Efficacy (E): The isomerization step governed by the equilibrium between AR and AR^*.
In ligand-gated ion channels, such as nicotinic receptors, different agonists do not change the "size" of the electrical current. Instead, a more efficacious agonist increases the probability or the duration that the channel remains in the "open" (AR^*) state.
6. Competitive Antagonism: The Schild Equation and Surmountability
Reversible competitive antagonism occurs when an agonist and antagonist compete for the same binding site. Atropine is the gold standard, surmountably blocking acetylcholine.
The Schild Protocol: A Step-by-Step for the Clinician-Scientist To characterize an antagonist like phentolamine, follow this protocol:
- Establish a control dose-response curve for the agonist alone.
- Introduce a fixed concentration of the antagonist (B) and measure the concentration ratio (r)—the factor by which you must increase the agonist to restore the original response.
- Plot \log(r-1) against \log[B](the Schild plot).
- Verify a slope of exactly 1.0. This confirms the antagonism is competitive and surmountable.
The parallel shift to the right of the log-concentration curve, without a decrease in maximal response, is the hallmark of this interaction. The x-intercept of this plot gives the pA_2 value (an empirical measure of potency).
7. Advanced Concepts: Constitutive Activity and Inverse Agonists
Some receptors exhibit constitutive activity, signaling even without a ligand (e.g., mutated TSH receptors in hyperthyroidism). In these systems, we classify ligands into three states:
- Positive Agonist: Increases activity above the basal "leak" level.
- Neutral Antagonist: Has equal affinity for both states; it blocks other ligands but does not change the basal signaling.
- Inverse Agonist (Negative Antagonist): Has a higher affinity for the inactive state, "turning off" the constitutive activity.
8. Clinical Pitfalls: Factors Distorting Pharmacology
Theory often hits a wall in the "Ward" reality. You must account for factors that distort the apparent potency of drugs:
- Uptake-1 (Neuronal Uptake): Sympathetic nerves actively pump noradrenaline out of the synapse. This clearance makes a competitive antagonist appear less potent than it actually is because the concentration at the receptor is lower than the concentration we administered. Blocking this pump with cocaine or through surgical denervation restores the "textbook" parallel shift and increases the concentration ratio.
- Desensitization & Downregulation: Tissues may "turn down the volume" through rapid phosphorylation (desensitization) or the actual internalizing and destruction of receptor proteins (downregulation).
9. Key Takeaways for Clinical Practice
- Affinity (K_A): The binding strength. When [A] = K_A, 50% of receptors are occupied.
- Efficacy (E): The activation power. It represents the ability of the AR complex to undergo isomerization to AR^* .
- Macroscopic Constant (K_{eff}): The measured equilibrium value, calculated as K_A / (1 + E).
- Schild Plot: A tool to prove competitive antagonism. A slope of 1.0 is mandatory for "simple" competition.
- pA_2 vs. pK_B: pA_2 is the negative log of the antagonist concentration that necessitates a doubling of the agonist (r=2). If the Schild slope is 1, pA_2 = pK_B.
- Partial Agonist: Can act as an antagonist when a full agonist is present (e.g., prenalterol vs. isoprenaline).
- Key Drugs to Know: Atropine (Muscarinic Antagonist), Isoprenaline (Full \beta-Agonist), Noradrenaline (Endogenous Agonist), Phentolamine (\alpha-Antagonist), Carbachol (Muscarinic Agonist), and Pilocarpine (Muscarinic Agonist).